IRX-616a Archives | Cannabiz

News in brief: Judgment reserved in CDA Clinics QLD legal case; Nexalis completes Phase 1 IRX-616a dosing

by Adam Sheldon May 18, 2026May 21, 2026

A judgment in the long-running legal dispute between the Therapeutic Goods Administration and CDA Clinics Queensland […]

News in brief: Nexalis advances IRX-616a and IRX-211 programs; Vitura heralds Doctors on Demand growth; Elixinol improves cash flow

by Adam Sheldon April 20, 2026April 22, 2026

Nexalis outlines 2026 plan as IRX shares jump 35%

by Adam Sheldon February 17, 2026February 19, 2026

Financial news in brief: Avecho; InhaleRx; Neurotech; Peak; Zelira; Argent

by Adam Sheldon February 2, 2026February 5, 2026

Elixinol records first underlying operating cash flow positive quarter

by Adam Sheldon February 2, 2026February 3, 2026

InhaleRx locks in A$1m cap raise and reveals plans to rebrand

by Adam Sheldon December 1, 2025February 21, 2026

News in brief: Losses widen for Avecho and Elixinol; InhaleRx secures HREC approval; Zelira cuts deficit; Argent shifts from ‘non-core’ activities

by Adam Sheldon August 29, 2025February 21, 2026

InhaleRx reports half-year loss but advances clinical trial plans

by Martin Lane August 26, 2025August 28, 2025

InhaleRx advances cancer pain and panic disorder trials

by Adam Sheldon July 23, 2025July 23, 2025

News in brief: Tilray launches pastilles; InhaleRx progresses panic disorder trial; NSW calls for hemp plan feedback; BS3 makes key hire

by Steve Jones and Martin Lane April 23, 2025April 23, 2025